Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations? (2020)
Attributed to:
Understanding synthetic lethality of ATR inhibitors with DDR dysregulation common in ovarian cancer
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.pharmthera.2019.107450
PubMed Identifier: 31836456
Publication URI: http://europepmc.org/abstract/MED/31836456
Type: Journal Article/Review
Parent Publication: Pharmacology & Therapeutics
ISSN: 0163-7258